VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Up 512.8% in March

VivoSim Labs, Inc. (NASDAQ:VIVS) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 91,217 shares, a growth of 512.8% from the March 15th total of 14,885 shares. Approximately 3.6% of the shares of the company are short sold. Based on an average trading volume of 134,350 shares, the days-to-cover ratio is presently 0.7 days.

VivoSim Labs Price Performance

Shares of VIVS opened at $1.45 on Friday. The firm has a market cap of $3.78 million, a PE ratio of -0.46 and a beta of 1.43. The stock’s fifty day moving average price is $1.88 and its two-hundred day moving average price is $2.18. VivoSim Labs has a 1 year low of $1.25 and a 1 year high of $5.30.

VivoSim Labs (NASDAQ:VIVS) last issued its earnings results on Wednesday, February 11th. The company reported ($1.03) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million during the quarter. VivoSim Labs had a negative net margin of 861.27% and a negative return on equity of 15.51%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of VivoSim Labs in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Trading of VivoSim Labs

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to its most recent filing with the SEC. The fund acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent filing with the SEC. Institutional investors own 8.23% of the company’s stock.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.